Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/139546
Title: | Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease |
Author: | Picón Pagès, Pol Bonet, Jaume García García, Javier Garcia Buendia, Joan Gutierrez, Daniela Valle, Javier Gómez Casuso, Carmen E.S. Sidelkivska, Valeriya Álvarez, Alejandra Perálvarez Marín, Alex Suades, Albert Fernàndez Busquets, Xavier Andreu, David Vicente García, Rubén, 1978- Oliva Miguel, Baldomero Muñoz, Francisco J. |
Keywords: | Malaltia d'Alzheimer Albúmines Alzheimer's disease Albumins |
Issue Date: | 26-Jun-2019 |
Publisher: | Elsevier |
Abstract: | Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ1–42 simulations was significantly lower than that of the clusterin-Aβ1–42 binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ1–42 incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1–42 aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ1–42 incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1016/j.csbj.2019.06.017 |
It is part of: | Computational and Structural Biotechnology Journal, 2019, vol. 17, p. 963-971 |
URI: | http://hdl.handle.net/2445/139546 |
Related resource: | http://dx.doi.org/10.1016/j.csbj.2019.06.017 |
ISSN: | 2001-0370 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Picon-PagesP_Comput_Struct_Biotechnol_J_2019.pdf | 629.82 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License